A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

NCT03334396 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company

Collaborators

[object Object]